LEADER 04202nam  22005895  450 
001 9910300267603321
005 20230810193209.0
010   $a3-319-73585-3
024 7 $a10.1007/978-3-319-73585-6
035   $a(CKB)4100000002892265
035   $a(MiAaPQ)EBC5356029
035   $a(DE-He213)978-3-319-73585-6
035   $a(PPN)22555125X
035   $a(EXLCZ)994100000002892265
100   $a20180313d2018      u|         0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aMyasthenia Gravis and Related Disorders /$fedited by Henry J. Kaminski, Linda L. Kusner
205   $a3rd ed. 2018.
210  1$aCham :$cSpringer International Publishing :$cImprint: Humana,$d2018.
215   $a1 online resource (357 pages) $cillustrations
225 1 $aCurrent Clinical Neurology,$x2524-4043
311   $a3-319-73584-5 
327   $aChapter 1. Neuromuscular Junction Physiology and Pathophysiology -- Chapter 2. Acetylcholine Receptor Structure -- Chapter 3. Immunopathogenesis of Myasthenia Gravis -- Chapter 4. Animal Models of Myasthenia Gravis for Preclinical Evaluation -- Chapter 5. Epidemiology and Genetics of Myasthenia Gravis -- Chapter 6. Clinical Presentations of Myasthenia Gravis -- Chapter 7. Ocular Myasthenia -- Chapter 8. Thymoma-associated Myasthenia Gravis -- Chapter 9. Electrodiagnosis of Neuromuscular Junction Disorders -- Chapter 10. Autoantibody Testing in the Diagnosis and Management of Autoimmune Disorders of Neuromuscular Transmission and Related Diseases -- Chapter 11. Treatment of Myasthenia Gravis -- Chapter 12. Neurocritical Care of Myasthenic Crisis -- Chapter 13. Thymectomy for Non-thymomatous Myasthenia Gravis -- Chapter 14. Lambert-Eaton Syndrome -- Chapter 15 Acquired Neuromyotonia -- Chapter 16. Congenital Myasthenic Syndromes -- Chapter 17. Toxic Neuromuscular Transmission Disorders -- Chapter 18. Predictors of Psychological Health in Myasthenia Gravis -- Chapter 19. Myasthenia Gravis: Classification and Outcome Measurements -- Chapter 20. Emerging Therapeutics for Myasthenia Gravis -- Chapter 21. Clinical Trial Design for Myasthenia Gravis.
330   $aThe third edition of this important, gold-standard title outlines a range of significant advances in the study and understanding of myasthenia gravis. The overarching goal of this new edition is identical to the first and second -- to provide the clinician and the scientist with a common resource for understanding the profound achievements in the clinical, translational, and basic sciences of neuromuscular transmission disorders. In addition to several new authors and an extensive update of all chapters, this third edition includes summaries of pre-clinical research standards for autoimmune MG, along with a broad summary of MG clinical trial performance. The now greater understanding of the clinical presentation of MuSK-related MG and identification of potential new autoantigens, including LRP-4, is discussed. The development of treatment guidelines by groups in Japan, the United Kingdom, Germany, and an international consortium is also outlined. Myasthenia Gravis and Related Disorders, Third Edition, is an invaluable resource for meeting the many and varied needs of clinicians who treat patients with myasthenia gravis.
410  0$aCurrent Clinical Neurology,$x2524-4043
606   $aNeurology
606   $aNeurosciences
606   $aImmunology
606   $aRespiratory organs$xDiseases
606   $aNeurology
606   $aNeuroscience
606   $aImmunology
606   $aPneumology
615  0$aNeurology.
615  0$aNeurosciences.
615  0$aImmunology.
615  0$aRespiratory organs$xDiseases.
615 14$aNeurology.
615 24$aNeuroscience.
615 24$aImmunology.
615 24$aPneumology.
676   $a573.7528
702   $aKaminski$b Henry J$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aKusner$b Linda L$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910300267603321
996   $aMyasthenia Gravis and Related Disorders$91756617
997   $aUNINA